Single-Pass Albumin Dialysis in the Treatment of Children with Liver Failure

Area of Science:

• Pediatric Hepatology
• Extracorporeal Liver Support
• Liver Transplantation

Background:

• Acute and acute on chronic liver failure are critical conditions in children, often requiring liver transplantation.
• Limited organ availability complicates pediatric liver transplantation.
• Existing extracorporeal liver support systems pose challenges due to large extracorporeal volumes in pediatric patients.

Purpose of the Study:

• To evaluate the efficacy and safety of single-pass albumin dialysis (SPAD) in pediatric patients with liver failure.
• To assess SPAD's impact on detoxification markers and clinical outcomes.
• To identify potential complications and optimal anticoagulation strategies for SPAD in children.

Main Methods:

• Retrospective review of pediatric patients with liver failure treated with SPAD.
• Measurement of serum bilirubin and ammonia levels to assess detoxification.
• Evaluation of hepatic encephalopathy (HE) improvement as a clinical outcome.
• Documentation of adverse events, including circuit clotting and need for supportive therapies.

Main Results:

• Nineteen pediatric patients (median age 25.5 months) received SPAD treatment.
• Significant reductions in total bilirubin (p < 0.001) and ammonia (p = 0.02) were observed.
• Hepatic encephalopathy (HE) significantly improved (p = 0.001), with 12 patients successfully bridged to liver transplantation.
• Circuit clotting occurred in 49% of sessions; heparin and citrate anticoagulation were superior to no anticoagulation (p=0.03).
• Blood product transfusion (57%) and catecholamine therapy (49%) were frequently required.

Conclusions:

• Single-pass albumin dialysis (SPAD) is an effective detoxification therapy for children with liver failure.
• SPAD demonstrates significant improvements in HE and laboratory parameters.
• Anticoagulation is crucial for managing SPAD circuit patency in pediatric patients.